{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T04:15:24Z","timestamp":1775880924422,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P3-0343"],"award-info":[{"award-number":["P3-0343"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P3-0003"],"award-info":[{"award-number":["P3-0003"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J7-4640"],"award-info":[{"award-number":["J7-4640"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J7-4537"],"award-info":[{"award-number":["J7-4537"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J3-4526"],"award-info":[{"award-number":["J3-4526"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J4-4563"],"award-info":[{"award-number":["J4-4563"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["L3-50111"],"award-info":[{"award-number":["L3-50111"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000783","name":"Research Executive Agency","doi-asserted-by":"publisher","award":["101059842"],"award-info":[{"award-number":["101059842"]}],"id":[{"id":"10.13039\/501100000783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011758","name":"Ministrstvo za visoko \u0161olstvo, znanost in tehnologijo","doi-asserted-by":"publisher","award":["3330-18-1115"],"award-info":[{"award-number":["3330-18-1115"]}],"id":[{"id":"10.13039\/501100011758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Gene therapy has transitioned from a long-awaited promise to a clinical reality, offering transformative treatments for rare congenital diseases and certain cancers, which have a significant impact on patients\u2019 lives. Current approaches focus on gene replacement therapy, either in vivo or ex vivo, mostly utilizing viral vectors to deliver therapeutic genes into target cells. However, refining these techniques is essential to overcome challenges and complications associated with gene therapy to ensure long-term safety and efficacy. Slovenia has witnessed significant advancements in this field since 2018, marked by successful gene therapy trials and treatments for various rare diseases. Significant strides have been made in the field of gene therapy in Slovenia, treating patients with spinal muscular atrophy and rare metabolic disorders, including the pioneering work on CTNNB1 syndrome. Additionally, immune gene therapy, exemplified by IL-12 adjuvant therapy for cancer, has been a focus of research in Slovenia. Through patient-centred initiatives and international collaborations, researchers in Slovenia are advancing preclinical research and clinical trials, paving the way for accessible gene therapies. Establishing clinical infrastructure and genomic diagnostics for rare diseases is crucial for gene therapy implementation. Efforts in this regard in Slovenia, including the establishment of a Centre for Rare Diseases, Centre for the Technologies of Gene and Cell Therapy, and rapid genomic diagnostics, demonstrate a commitment to comprehensive patient care. Despite the promises of gene therapy, challenges remain, including cost, distribution, efficacy, and long-term safety. Collaborative efforts are essential to address these challenges and ensure equitable access to innovative therapies for patients with rare diseases.<\/jats:p>","DOI":"10.1186\/s13023-025-03828-8","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T14:00:36Z","timestamp":1749132036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gene therapy of rare diseases as a milestone in medicine - overview of the field and report on initial experiences in Slovenia"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5246-9869","authenticated-orcid":false,"given":"Urh","family":"Gro\u0161elj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-1344","authenticated-orcid":false,"given":"Marko","family":"Kav\u010di\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-2919","authenticated-orcid":false,"given":"Ana","family":"Drole Torkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4159-1783","authenticated-orcid":false,"given":"Jan","family":"Kafol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-5441","authenticated-orcid":false,"given":"Du\u0161ko","family":"Lain\u0161\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-5251","authenticated-orcid":false,"given":"Roman","family":"Jerala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matja\u017e","family":"Sever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-7923","authenticated-orcid":false,"given":"Samo","family":"Zver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-5670","authenticated-orcid":false,"given":"Gregor","family":"Ser\u0161a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1928","authenticated-orcid":false,"given":"Maja","family":"\u010cema\u017ear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-112X","authenticated-orcid":false,"given":"Primo\u017e","family":"Strojan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ale\u0161","family":"Gro\u0161elj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-5120","authenticated-orcid":false,"given":"Mojca","family":"\u017derjav Tan\u0161ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5004-0607","authenticated-orcid":false,"given":"\u0160pela","family":"Miro\u0161evi\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Ivan\u010dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toma\u017e","family":"Prelog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gosar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasna","family":"Ora\u017eem Mrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1143-2880","authenticated-orcid":false,"given":"Matej","family":"Mlinari\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bertok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-4838","authenticated-orcid":false,"given":"Jernej","family":"Kova\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Kodri\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-0573","authenticated-orcid":false,"given":"Saba","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2341-2791","authenticated-orcid":false,"given":"Marko","family":"Pokorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-1212","authenticated-orcid":false,"given":"Alojz","family":"Ihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-1591","authenticated-orcid":false,"given":"Janez","family":"Jazbec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-4732","authenticated-orcid":false,"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2188-420X","authenticated-orcid":false,"given":"Damjan","family":"Osredkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"11\/12","key":"3828_CR1","first-page":"507","volume":"91","author":"T Jal\u0161ovec","year":"2022","unstructured":"Jal\u0161ovec T, Lah B, Bernardo ME, Drole Torkar A, Kodri\u010d J, \u017derjav-Tan\u0161ek M, et al. Prikaz primera prvega uspe\u0161nega genskega zdravljenja slovenskega bolnika z mukopolisaharidozo tipa I v tujini. Zdravni\u0161ki Vestnik. 2022;91(11\/12):507\u201315.","journal-title":"Zdravni\u0161ki Vestnik"},{"issue":"2","key":"3828_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.38031\/slovpediatr-2022-2-02","volume":"29","author":"B Lah","year":"2022","unstructured":"Lah B, Jal\u0161ovec T, Drole Torkar A, Kodri\u010d J, Battelino S, \u017derjav Tan\u0161ek M, et al. Gensko zdravljenje pri mukopolisaharidozi tipa IIIa: predstavitev primerov. Slov Pediatrija. 2022;29(2):66\u201371.","journal-title":"Slov Pediatrija"},{"key":"3828_CR3","doi-asserted-by":"publisher","first-page":"915342","DOI":"10.3389\/fphar.2022.915342","volume":"13","author":"C Jommi","year":"2022","unstructured":"Jommi C, Bramanti S, Pani M, Ghirardini A, Santoro A. CAR T-Cell therapies in Italy: patient access barriers and recommendations for health system solutions. Front Pharmacol. 2022;13:915342.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3828_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"3828_CR5","unstructured":"Albreht T, Polin K, Pribakovic Brinovec R, Kuhar M, Poldrugovac M, Ogrin Rehberger P, et al. Slovenia: Health Syst Rev Health Syst Transit. 2021;23(1):1\u2013183."},{"issue":"3","key":"3828_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2478\/raon-2022-0021","volume":"56","author":"A Groselj","year":"2022","unstructured":"Groselj A, Bosnjak M, Jesenko T, Cemazar M, Markelc B, Strojan P, et al. Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: a first-in-human clinical trial protocol. Radiol Oncol. 2022;56(3):398\u2013408.","journal-title":"Radiol Oncol"},{"key":"3828_CR7","unstructured":"Vr\u0161\u010daj E, Golli T, Loboda T, Piskar A, Homan M, Osredkar D. The first patients receiving gene-replacement therapy in Slovenia; two children with spinal muscular atrophy treated with omnasemnogene abeparvovek. Slovenian Med J. 2024."},{"issue":"6","key":"3828_CR8","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","volume":"30","author":"K Cornetta","year":"2022","unstructured":"Cornetta K, Bonamino M, Mahlangu J, Mingozzi F, Rangarajan S, Rao J. Gene therapy access: global challenges, opportunities, and views from Brazil, South Africa, and India. Mol Ther. 2022;30(6):2122\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"3828_CR9","first-page":"12","volume":"26","author":"M \u010cema\u017ear","year":"2022","unstructured":"\u010cema\u017ear M, Jesenko T, Bo\u0161njak M, Markelc B, Kamen\u0161ek U, Kranjc Brezar S, et al. Genska terapija v onkologiji, prvi razvojni koraki v Sloveniji. Onkologija: strokovno-znanstveni \u010casopis Za Zdravnike. 2022;26(1):12\u201321.","journal-title":"Onkologija: strokovno-znanstveni \u010casopis Za Zdravnike"},{"key":"3828_CR10","doi-asserted-by":"crossref","unstructured":"Kos S, Bosnjak M, Jesenko T, Markelc B, Kamensek U, Znidar K, et al. Non-clinical in vitro evaluation of antibiotic resistance gene-free plasmids encoding human or murine IL-12 intended for first-in-human clinical study. Pharmaceutics. 2021;13(10).","DOI":"10.3390\/pharmaceutics13101739"},{"issue":"2","key":"3828_CR11","doi-asserted-by":"publisher","first-page":"e08879","DOI":"10.1016\/j.heliyon.2022.e08879","volume":"8","author":"U Kamensek","year":"2022","unstructured":"Kamensek U, Rencelj A, Jesenko T, Remic T, Sersa G, Cemazar M. Maintenance and gene electrotransfer efficiency of antibiotic resistance gene-free plasmids encoding mouse, canine and human interleukin-12 orthologues. Heliyon. 2022;8(2):e08879.","journal-title":"Heliyon"},{"key":"3828_CR12","doi-asserted-by":"crossref","unstructured":"Mirosevic S, Khandelwal S, Susjan P, Zakelj N, Gosar D, Forstneric V, et al. Correlation between phenotype and genotype in CTNNB1 syndrome: a systematic review of the literature. Int J Mol Sci. 2022;23(20).","DOI":"10.3390\/ijms232012564"},{"issue":"1","key":"3828_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-019-1146-x","volume":"14","author":"D Stanimirovic","year":"2019","unstructured":"Stanimirovic D, Murko E, Battelino T, Groselj U. Development of a pilot rare disease registry: a focus group study of initial steps towards the establishment of a rare disease ecosystem in Slovenia. Orphanet J Rare Dis. 2019;14(1):172.","journal-title":"Orphanet J Rare Dis"},{"issue":"10426","key":"3828_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(23)01952-9","volume":"403","author":"A Schambach","year":"2024","unstructured":"Schambach A, Buchholz CJ, Torres-Ruiz R, Cichutek K, Morgan M, Trapani I, et al. A new age of precision gene therapy. Lancet. 2024;403(10426):568\u201382.","journal-title":"Lancet"},{"issue":"5","key":"3828_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.5966\/sctm.2013-0206","volume":"3","author":"DA Williams","year":"2014","unstructured":"Williams DA, Thrasher AJ. Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl Med. 2014;3(5):636\u201342.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"3828_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ng1092-93","volume":"2","author":"T Friedmann","year":"1992","unstructured":"Friedmann T. A brief history of gene therapy. Nat Genet. 1992;2(2):93\u20138.","journal-title":"Nat Genet"},{"issue":"11","key":"3828_CR17","first-page":"1612","volume":"164","author":"B Sibbald","year":"2001","unstructured":"Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612.","journal-title":"CMAJ"},{"issue":"4","key":"3828_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.hoc.2022.05.001","volume":"36","author":"HL Malech","year":"2022","unstructured":"Malech HL, Garabedian EK, Hsieh MM. Evolution of gene therapy, historical perspective. Hematol Oncol Clin North Am. 2022;36(4):627\u201345.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3828_CR19","doi-asserted-by":"publisher","first-page":"e5009","DOI":"10.1136\/bmj.e5009","volume":"345","author":"G Watts","year":"2012","unstructured":"Watts G. Gene therapy to be authorised for first time in EU. BMJ. 2012;345:e5009.","journal-title":"BMJ"},{"issue":"6","key":"3828_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nbt0617-491","volume":"35","author":"M Senior","year":"2017","unstructured":"Senior M. After Glybera\u2019s withdrawal, what\u2019s next for gene therapy? Nat Biotechnol. 2017;35(6):491\u20132.","journal-title":"Nat Biotechnol"},{"issue":"6096","key":"3828_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321.","journal-title":"Science"},{"issue":"7829","key":"3828_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/d41586-020-02765-9","volume":"586","author":"H Ledford","year":"2020","unstructured":"Ledford H, Callaway E. Pioneers of revolutionary CRISPR gene editing win chemistry nobel. Nature. 2020;586(7829):346\u20137.","journal-title":"Nature"},{"issue":"1","key":"3828_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00438-022-01978-z","volume":"298","author":"A Khiabani","year":"2023","unstructured":"Khiabani A, Kohansal MH, Keshavarzi A, Shahraki H, Kooshesh M, Karimzade M, et al. CRISPR\/Cas9, a promising approach for the treatment of beta-thalassemia: a systematic review. Mol Genet Genomics. 2023;298(1):1\u201311.","journal-title":"Mol Genet Genomics"},{"issue":"4","key":"3828_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/iep.12478","volume":"104","author":"I Papaioannou","year":"2023","unstructured":"Papaioannou I, Owen JS, Yanez-Munoz RJ. Clinical applications of gene therapy for rare diseases: a review. Int J Exp Pathol. 2023;104(4):154\u201376.","journal-title":"Int J Exp Pathol"},{"issue":"2","key":"3828_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jgg.2023.08.001","volume":"51","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wu ZY. Gene therapy for monogenic disorders: challenges, strategies, and perspectives. J Genet Genomics. 2024;51(2):133\u201343.","journal-title":"J Genet Genomics"},{"key":"3828_CR26","doi-asserted-by":"crossref","unstructured":"Oliynyk RT. Future preventive gene therapy of polygenic diseases from a population genetics perspective. Int J Mol Sci. 2019;20(20).","DOI":"10.3390\/ijms20205013"},{"issue":"S1","key":"3828_CR27","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3\u20139.","journal-title":"Am J Hematol"},{"issue":"7573","key":"3828_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351\u201360.","journal-title":"Nature"},{"key":"3828_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/5584_2019_463","volume":"1247","author":"B Arjmand","year":"2020","unstructured":"Arjmand B, Larijani B, Sheikh Hosseini M, Payab M, Gilany K, Goodarzi P, et al. The horizon of gene therapy in modern medicine: advances and challenges. Adv Exp Med Biol. 2020;1247:33\u201364.","journal-title":"Adv Exp Med Biol"},{"key":"3828_CR30","doi-asserted-by":"crossref","unstructured":"Ho BX, Loh SJH, Chan WK, Soh BS. In vivo genome editing as a therapeutic approach. Int J Mol Sci. 2018;19(9).","DOI":"10.3390\/ijms19092721"},{"key":"3828_CR31","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1016\/j.csbj.2022.06.015","volume":"20","author":"X Wu","year":"2022","unstructured":"Wu X, He X, Liu F, Jiang X, Wang P, Zhang J, et al. Development and clinical translation of ex vivo gene therapy. Comput Struct Biotechnol J. 2022;20:2986\u20133003.","journal-title":"Comput Struct Biotechnol J"},{"key":"3828_CR32","doi-asserted-by":"publisher","first-page":"1148693","DOI":"10.3389\/fgeed.2023.1148693","volume":"5","author":"R Murugesan","year":"2023","unstructured":"Murugesan R, Karuppusamy KV, Marepally S, Thangavel S. Current approaches and potential challenges in the delivery of gene editing cargos into hematopoietic stem and progenitor cells. Front Genome Ed. 2023;5:1148693.","journal-title":"Front Genome Ed"},{"key":"3828_CR33","doi-asserted-by":"crossref","unstructured":"Volodina O, Smirnikhina S. The future of gene therapy: a review of in vivo and ex vivo delivery methods for genome editing-based therapies. Mol Biotechnol. 2024.","DOI":"10.1007\/s12033-024-01070-4"},{"issue":"2","key":"3828_CR34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1021\/acschembio.7b00680","volume":"13","author":"RC Wilson","year":"2018","unstructured":"Wilson RC, Gilbert LA. The promise and challenge of in vivo delivery for genome therapeutics. ACS Chem Biol. 2018;13(2):376\u201382.","journal-title":"ACS Chem Biol"},{"issue":"10\u201311","key":"3828_CR35","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","volume":"30","author":"DB Kohn","year":"2023","unstructured":"Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Ther. 2023;30(10\u201311):738\u201346.","journal-title":"Gene Ther"},{"issue":"6","key":"3828_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/mt.2016.20","volume":"24","author":"SJ Gray","year":"2016","unstructured":"Gray SJ. Timing of gene therapy interventions: the earlier, the better. Mol Ther. 2016;24(6):1017\u20138.","journal-title":"Mol Ther"},{"issue":"1","key":"3828_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1535676019899502","volume":"25","author":"S Ghosh","year":"2020","unstructured":"Ghosh S, Brown AM, Jenkins C, Campbell K. Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Appl Biosaf. 2020;25(1):7\u201318.","journal-title":"Appl Biosaf"},{"issue":"9","key":"3828_CR38","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.jtha.2023.06.016","volume":"21","author":"LA Valentino","year":"2023","unstructured":"Valentino LA, Kaczmarek R, Pierce GF, Noone D, O\u2019Mahony B, Page D, et al. Hemophilia gene therapy: first, do no harm. J Thromb Haemost. 2023;21(9):2354\u201361.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3828_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0091270004273680","volume":"45","author":"CM Smith","year":"2005","unstructured":"Smith CM. Origin and uses of primum non nocere\u2013above all, do no harm! J Clin Pharmacol. 2005;45(4):371\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"3828_CR40","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2217\/rme-2021-0159","volume":"17","author":"M Sharpe","year":"2022","unstructured":"Sharpe M, Beswick L, Kefalas P. Using analogue data to substantiate long-term durability of gene therapies: a narrative review. Regen Med. 2022;17(10):767\u201382.","journal-title":"Regen Med"},{"issue":"4","key":"3828_CR41","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30(4):1364\u201380.","journal-title":"Mol Ther"},{"issue":"1","key":"3828_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"3828_CR43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.34172\/jcvtr.2022.14","volume":"14","author":"N Roshanravan","year":"2022","unstructured":"Roshanravan N, Tutunchi H, Najafipour F, Dastouri M, Ghaffari S, Jebeli A. A glance at the application of CRISPR\/Cas9 gene-editing technology in cardiovascular diseases. J Cardiovasc Thorac Res. 2022;14(2):77\u201383.","journal-title":"J Cardiovasc Thorac Res"},{"issue":"5","key":"3828_CR44","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa2309149","volume":"390","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, et al. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N Engl J Med. 2024;390(5):432\u201341.","journal-title":"N Engl J Med"},{"issue":"10","key":"3828_CR45","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.3390\/cimb44100341","volume":"44","author":"R Mashima","year":"2022","unstructured":"Mashima R, Takada S. Lipid nanoparticles: a novel gene delivery technique for clinical application. Curr Issues Mol Biol. 2022;44(10):5013\u201327.","journal-title":"Curr Issues Mol Biol"},{"issue":"4","key":"3828_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313\u201320.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"3828_CR47","first-page":"247","volume":"25","author":"U Gro\u0161elj","year":"2018","unstructured":"Gro\u0161elj U, Kova\u010d J, Mlinari\u010d M, \u0160u\u0161tar U, Trebu\u0161ak Podkraj\u0161ek K, Battelino T. Program populacijskega testiranja holesterola za presejanje dru\u017einske hiperholesterolemije pri pred\u0161olskih otrocih v Sloveniji. Slov Pediatrija. 2018;25(3):247\u201359.","journal-title":"Slov Pediatrija"},{"key":"3828_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm11226773","volume":"11","author":"Q Fu","year":"2022","unstructured":"Fu Q, Hu L, Shen T, Yang R, Jiang L. Recent advances in gene therapy for familial hypercholesterolemia: an update review. J Clin Med. 2022;11(22).","journal-title":"J Clin Med"},{"key":"3828_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"WM Pardridge","year":"2019","unstructured":"Pardridge WM. Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. 2019;11:373.","journal-title":"Front Aging Neurosci"},{"key":"3828_CR50","doi-asserted-by":"crossref","unstructured":"Gomez Limia C, Baird M, Schwartz M, Saxena S, Meyer K, Wein N. Emerging perspectives on gene therapy delivery for neurodegenerative and neuromuscular disorders. J Pers Med. 2022;12(12).","DOI":"10.3390\/jpm12121979"},{"issue":"2","key":"3828_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","volume":"28","author":"T Taghian","year":"2020","unstructured":"Taghian T, Marosfoi MG, Puri AS, Cataltepe OI, King RM, Diffie EB, et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol Ther. 2020;28(2):411\u201321.","journal-title":"Mol Ther"},{"issue":"3","key":"3828_CR52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-221560","volume":"10","author":"RS Finkel","year":"2023","unstructured":"Finkel RS, Darras BT, Mendell JR, Day JW, Kuntz NL, Connolly AM, et al. Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG). J Neuromuscul Dis. 2023;10(3):389\u2013404.","journal-title":"J Neuromuscul Dis"},{"key":"3828_CR53","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/IJN.S61288","volume":"9","author":"CT Lu","year":"2014","unstructured":"Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed. 2014;9:2241\u201357.","journal-title":"Int J Nanomed"},{"key":"3828_CR54","doi-asserted-by":"crossref","unstructured":"Want MY, Bashir Z, Najar RA. T cell based immunotherapy for cancer: approaches and strategies. Vaccines (Basel). 2023;11(4).","DOI":"10.3390\/vaccines11040835"},{"key":"3828_CR55","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049.","journal-title":"Front Immunol"},{"issue":"4","key":"3828_CR56","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735\u201342.","journal-title":"Nat Med"},{"key":"3828_CR57","doi-asserted-by":"crossref","unstructured":"Giorgioni L, Ambrosone A, Cometa MF, Salvati AL, Magrelli A. CAR-T state of the art and future challenges, a regulatory perspective. Int J Mol Sci. 2023;24(14).","DOI":"10.3390\/ijms241411803"},{"issue":"1","key":"3828_CR58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","volume":"14","author":"DG Maloney","year":"2021","unstructured":"Maloney DG, Kuruvilla J, Liu FF, Kostic A, Kim Y, Bonner A, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. J Hematol Oncol. 2021;14(1):140.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3828_CR59","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"8","key":"3828_CR60","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Volkl S, et al. CD19 CAR T-Cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"key":"3828_CR61","doi-asserted-by":"crossref","unstructured":"Mullard A. CAR-T therapy for multiple sclerosis enters US trials for first time. Nature. 2024.","DOI":"10.1038\/d41586-024-00470-5"},{"key":"3828_CR62","unstructured":"Ihan A. CAR-T Celi\u010dna terapija za zdravljenje razli\u010dnih rakov in drugih bolezni. Napredne celi\u010dne terapije v univerzitetnem klini\u010dnem centru Ljubljana: zbornik sre\u010danja: univerzitetni klini\u010dni center, center za klini\u010dne raziskave. 2022. pp. 74\u201384."},{"key":"3828_CR63","unstructured":"Bolte\u017ear L, Andlovic A. CAR-T za zdravljenje limfomov in njihovi ne\u017eeleni u\u010dinki. Dnevi internisti\u010dne onkologije 2024: inovativna zdravila v onkologiji. Sekcija za internisti\u010dno onkologijo SZD; 2024. pp. 13\u20138."},{"issue":"11","key":"3828_CR64","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79(11):1255\u201362.","journal-title":"Drugs"},{"issue":"10322","key":"3828_CR65","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet. 2022;399(10322):372\u201383.","journal-title":"Lancet"},{"issue":"10","key":"3828_CR66","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3828_CR67","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"3828_CR68","first-page":"213","volume":"272","author":"D Stanimirovi\u0107","year":"2020","unstructured":"Stanimirovi\u0107 D, Murko E, Battelino T, Groselj U. Charting early developmental trajectory of a pilot rare disease registry in Slovenia. Stud Health Technol Inform. 2020;272:213\u20136.","journal-title":"Stud Health Technol Inform"},{"key":"3828_CR69","doi-asserted-by":"crossref","unstructured":"Rant \u017d, Groselj U, Stanimirovi\u0107 D. Metodologija izgradnje registra redkih nemalignih bolezni v Sloveniji \/ methodology for the development of a registry of rare non-malignant diseases in Slovenia. 42nd International Conference on Organizational Science Development: Interdisciplinarity Counts; March 2023; Portoro\u017e, Slovenia. 2023.","DOI":"10.18690\/um.fov.3.2023.70"},{"issue":"11","key":"3828_CR70","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1016\/j.gim.2022.08.006","volume":"24","author":"S Kayumi","year":"2022","unstructured":"Kayumi S, Perez-Jurado LA, Palomares M, Rangu S, Sheppard SE, Chung WK, et al. Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants. Genet Med. 2022;24(11):2351\u201366.","journal-title":"Genet Med"},{"issue":"14","key":"3828_CR71","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","volume":"2","author":"N Machin","year":"2018","unstructured":"Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia a: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792\u20138.","journal-title":"Blood Adv"},{"key":"3828_CR72","doi-asserted-by":"crossref","unstructured":"Gene therapies should be for all. Nat Med. 2021;27(8):1311.","DOI":"10.1038\/s41591-021-01481-9"},{"key":"3828_CR73","doi-asserted-by":"crossref","unstructured":"Fox TA, Booth C. Improving access to gene therapy for rare diseases. Dis Model Mech. 2024;17(6).","DOI":"10.1242\/dmm.050623"},{"issue":"3","key":"3828_CR74","first-page":"e36197","volume":"15","author":"T Ogbonmide","year":"2023","unstructured":"Ogbonmide T, Rathore R, Rangrej SB, Hutchinson S, Lewis M, Ojilere S, et al. Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma). Cureus. 2023;15(3):e36197.","journal-title":"Cureus"},{"issue":"8","key":"3828_CR75","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s10198-022-01548-5","volume":"24","author":"SHS Chan","year":"2023","unstructured":"Chan SHS, Wong CKH, Wu T, Wong W, Yu MKL, Au ICH, et al. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data. Eur J Health Econ. 2023;24(8):1373\u201382.","journal-title":"Eur J Health Econ"},{"issue":"17\u201318","key":"3828_CR76","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1089\/hum.2023.152","volume":"34","author":"JA Bueren","year":"2023","unstructured":"Bueren JA, Auricchio A. Advances and challenges in the development of gene therapy medicinal products for rare diseases. Hum Gene Ther. 2023;34(17\u201318):763\u201375.","journal-title":"Hum Gene Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03828-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03828-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03828-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:03:46Z","timestamp":1749135826000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03828-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3828"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03828-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. Kodri\u010d received compensation for consulting services provided to Abeona Therapeutics (Ohio, United States of America) which was acquired by Ultragenyx (California, United States of America) in 2021. Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}